RecruitingPhase 4

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

Switzerland500 participantsStarted 2023-03-17

Plain-language summary

The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.

Age range6 Months – 6 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Informed Consent as documented by signature
✓. 6-month-old children
✓. In overall good health, without any clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) and no clinically significant abnormal finding on history and/or physical examination
✓. Fully immunised for age according to the Swiss vaccination schedule
✓. with at least 2 doses of DTP-containing vaccine
✓. the last dose of vaccine received at least 2 weeks prior to enrolment

✕. Contra-indications to MMR, including
✕. immunosuppression (i.e. proven, suspected, or planned)
✕. allergy to a component of the vaccine
✕. receipt of a live-attenuated vaccine in the four weeks prior to inclusion
✕. Vaccine refusal
✕. Indication for an early MMR vaccination, including
✕. Measles outbreak
✕. Planned immunosuppression (indication to an accelerated schedule to be completed before starting an immunosuppressive treatment)

Incidence of respiratory infection within the 3 months following randomisation

Timeframe: Measured over the 3 months following randomisation

NCT IDNCT05758532

SponsorLaure Pittet, MD-PhD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04

Laure F Pittet, MD-PhD